

DAFTAR PUSTAKA

1. Song M, Zhang Q, Song C, Liu T, Zhang X, Ruan G, et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. *J Cachexia Sarcopenia Muscle*. 2022;13(5):2504–14.
2. Ferlay J, Rebecca ME, Mph LS. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2024;(February):229–63.
3. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. *Respirology*. 2015;20(4):654–9.
4. Yang L, Wang Y. Malignant pleural effusion diagnosis and therapy. *Open Life Sci*. 2023;18(1).
5. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC Cancer* [Internet]. 2013;13(1):158–65. Available from: BMC Cancer
6. Alawneh A. Validating LENT score in malignant pleural effusion. *Futur Sci OA*. 2024;10(2144):0168–89.
7. Emin A. Can LENT Prognostic score (LDH , ECOG performance score , blood neutrophil / lymphocyte ratio , tumor type) change the clinical approach in malignant pleural effusion ? 2021;69(2):133–43.
8. Kesehatan K, Indonesia R. Rencana kanker nasional 2024-2034. 2024;(September):1–132.
9. Aliyah N, Pranggono E, Andriyoko B. Kanker Paru: Sebuah Kajian Singkat. *Indones J Chest Emerg Med*. 2016;4(1):28–32.
10. Sakti BT, Rosalina R, Pradipta J. Characteristics of Chest X-Ray in Patients with Cancer at the Dharmais Cancer Hospital Emergency Room during the COVID-19 Pandemic. *Indones J Cancer*. 2021;15(4):p195-8.
11. Samper GJ, Herrera S, Estrella L, Marco J, Rafael B, Lapiedra A, et al.

Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical , Radiological and Pleural Fluid Analytical Parameters. Radiol Pleural Fluid Anal Parameters. 2017;201(195):p653–60.

12. Afriani A, Ermayanti S, Firdaus D. Evaluating the Prognostic Impact of the Systemic Immune- Inflammation Index On One-Year Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy : Initial Findings From West Sumatra, Indonesia. Pakistan Journal of Life & Social Sciences. 2025;23:7966–72.
13. Chen W, Shao J, Yang Y, Meng Y, Huang S, Liu J, et al. Prognostic significance of systemic immune inflammatory index in NSCLC : a. Lung Cancer Manag. 2024;10(221):1–11.
14. Zhang Y, Chen B. Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer : A Meta-Analysis. Dis Markers. 2019;1(7).
15. Jaya VP, Riyanto BS, Sumardi. ALI (Advanced Lung Cancer Inflammation Index) Sebagai Faktor Prognostik Mortalitas Adenokarsinoma Paru *Stage IV* di RSUP Dr Sardjito. Universitas Gajah Mada; 2020.
16. Horino T, Tokunaga R, Miyamoto Y, Baba H. Advanced Lung Cancer Inflammation Index : A Novel Comprehensive Biomarker of Host Status for Patients with Metastatic Colorectal Cancer. Journal of the anus, rectum and colon. 2024;8(3):137-49.
17. Pang H, Chen X, Yan M. Clinical significance of the advanced lung cancer inflammation index in gastrointestinal cancer patients : a systematic review and meta-analysis. Frontiers in oncology. 2023;(June):1–9.
18. Hua X, Chen J, Wu Y, Sha J, Han S, Zhu X. Prognostic role of the advanced lung cancer inflammation index in cancer patients: A meta-analysis. World J Surg Oncol. 2019;17(1):1–9.
19. Azka L, Sabrina Ermayanti, Russilawati, Irvan Medison, Deddy Herman, Fenty Anggraininy. LENT Score as a Prognosis Factor for Overall Survival and Progression-Free Survival in Malignant Pleural Effusion Patients at

- Tertiary Hospitals in West Sumatera, Indonesia. Vol. 7, Bioscientia Medicina : Journal of Biomedicine and Translational Research. 2023. p. 3393–8.
20. Shehata SM, Sileem AE, El-Fakharany KM. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. *Egyptian Journal of Chest Diseases and Tuberculosis*. 2015;64(3):593-9.
 21. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor. *Brain pathology*. 2016 Jan;26(1):3-17.
 22. Rawat D, Chhonker SK, Naik RA, Mehrotra A, Kumar S. Lactate as a signaling molecule : Journey from dead end product of glycolysis to tumor survival 4 . *Lactate metabolism and cancer*. 2019;(1):366–81.
 23. Abisheganaden J, Verma A, Dagaonkar RS, Light RW. An observational study evaluating the performance of LENT score in the selected population of malignant pleural effusion from lung adenocarcinoma in Singapore. *Respiration*. 2018;96(4):308-13.
 24. Bibby AC, Clive AO, Slade GC, Morley AJ, Fallon J, Psallidas I, et al. Survival in patients with malignant pleural effusions who developed pleural infection: A retrospective case review from six UK centers. *Chest [Internet]*. 2015;148(1):235–41. Available from: <http://dx.doi.org/10.1378/chest.14-2199>
 25. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score. *Thorax*. 2014;69(12):1098–104.
 26. Buonacera A, Stancanelli B, Colaci M. Neutrophil to Lymphocyte Ratio : An Emerging Marker of the Relationships between the Immune System and Diseases. *International journal of molecular sciences*. 2022;23(7):3636-42
 27. Nasution HN, Ashariati A, Kedokteran F, Muhammadiyah U, Airlangga-surabaya FKU. Kaheksia kanker dan tatalaksana nutrisi pada penderita kanker 1. 2021;21(2):189–96.

28. Chen Y, Liu T, Feng H, Liu T, Zhang J, Wang J, et al. The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy : a retrospective study. *Translational Lung Cancer Research*. 2024;13(6):1307–17.
29. Xie C, Chen J, Chen Z, Xu Y, Liu J, Zhang H, et al. Clinical eHealth Assessment of albumin and overall survival in advanced non-small cell lung cancer patients with anlotinib treatment using generalized additive model : A retrospective cohort study. *Clin eHealth* [Internet]. 2023;6:121–9. Available from: <https://doi.org/10.1016/j.cej.2023.09.003>
30. Kwon YJ, Yoon YC, Kim HS, Cha MJ, Park S, Lee JH. Prognostic significance of body mass index in small-cell lung cancer : Exploring the relationship with skeletal muscle status. *Journal of Cachexia, Sarcopenia and Muscle*. 2023;(November):2939–47.
31. Sezgin Y, Sakin A. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer. 2024;1–6.
32. Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. *Interactive CardioVascular and Thoracic Surgery*. 2016;23(May):560–6.
33. Georgakopoulou VE, Lempesis IG, Trakas N, Sklapani P, He Y, Spandidos DA. Lung cancer and obesity : A contentious relationship. *Oncology Reports*. 2024;52(5):158–68.
34. Andayani N, Arliny Y. The Correlation of Neutrophil-Lymphocyte Ratio (NLR) and the Response Evaluation Criteria in Solid Tumors (RECIST) in Non-small Cell Lung Cancer (NSCLC) Patient. *Indonesian Journal of Cancer* 2024;18(3):317–21.
35. Ary D, Dewi M, Setyawan UA, Brawijaya U. Neutrophil-Lymphocyte Ratio (NLR) as a Prognostic Marker in Advanced Lung Cancer Patients Undergoing First-Line Treatment. *J Respi*. 2024;10(03):209–13.
36. Peng B, Wang Y, Liu Y, Ma L. Prognostic significance of the neutrophil to

lymphocyte ratio in patients with non-small cell lung cancer : a systemic review and meta-analysis. *International journal of clinical and experimental medicine*. 2015;8(3):3098–106.

37. Ozyurek BA, Ozdemirel TS, Ozden SB, Erdogan Y, Kaplan B, Kaplan T. Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases. *Asian Pac J Cancer Prev*. 2017;18(5):1417–21.
38. Deng T, Zhang J, Meng Y, Zhou Y, Li W. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer. *Medicine*. 2018;97(38):38-45.
39. Wang S, Lv J, Lv J, Li H, Liu C, Jiang H, et al. Prognostic value of lactate dehydrogenase in non-small cell lung cancer patients with brain metastases : a retrospective cohort study. *Journal of Thoracic Disease*. 2022;14(11):4468–81.
40. Li Y, Wang K, Zhao E, Li B, Li S, Dong X, et al. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma. *Pathology and Oncology Research*. 2022;28(June):1–9.
41. Zheng N, Zhu D, Han Y. Procalcitonin and C-reactive protein perform better than the neutrophil/lymphocyte count ratio in evaluating hospital acquired pneumonia. *BMC Pulm Med*. 2020;20(1):1–10.
42. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al. Prevalence , Causes , and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China. *JAMA Network Open*. 2021;4(8):6–10.
43. Archive CDC. CDC Archive Smoking Status Recodes These resources from past NHIS years are available for use by [Internet]. Centers for Disease Control and Prevention. 1996 [cited 2025 Nov 21]. p. 1–12. Available from: https://archive.cdc.gov/www_cdc_gov/nchs/nhis/tobacco/tobacco_recodes.htm
44. Wicaksono A, Putra AC. The Impact of Smoking Degree on One Year Survival of Non-Small Cell Lung Cancer (NSCLC) at Persahabatan

- Hospital Cell Lung Cancer (NSCLC) Patients at Persahabatan Hospital. Jurnal Epidemiologi Kesehatan Indonesia. 2024;8(2).
45. Syahrudin E, Soeroso NN, Ananda FR, Wulandari L. The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia. J Respirol. 2025;11(79):22–30.
 46. Song M, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, et al. Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. Journal of the National Cancer Institute. 2017;109:1–18.
 47. Yoo J, Ph D, Lee Y, Ph D, Park Y, Lee J, et al. Update in Association between Lung Cancer and Air Pollution. Tuberc Respir Dis (Seoul). 2025;88(2):228–36.
 48. Wang M, Kim RY, Kohonen-corish MRJ, Chen H, Donovan C, Oliver BG. Particulate matter air pollution as a cause of lung cancer : epidemiological and experimental evidence. Br J Cancer [Internet]. 2025;(October 2024). Available from: <http://dx.doi.org/10.1038/s41416-025-02999-2>
 49. Yang WEI, Huang J, Wu HUI, Wang Y, Du Z, Ling Y, et al. Molecular mechanisms of cancer cachexia - induced muscle atrophy (Review). Mol Med Rep. 2020;22(6):4967–80.
 50. Neshan M, Tsilimigras DI, Han X, Zhu H. Molecular Mechanisms of Cachexia : A Review. Cells. 2024;13(3):1–17.
 51. Wang Y, Lin L, Ji Y, Mei X, Zhao C, Chen Y, et al. Prognostic value of the advanced lung cancer inflammation index in early-*stage* non-small cell lung cancer patients undergoing video-assisted thoracoscopic pulmonary resection. Annals of palliative medicine. 2020;9(3):721–9.
 52. Kusumawardhani E, Hadiani NF. Albumin Levels before Therapy and Clinicopathological Parameters of Lung Cancer Patients. Majalah Biomorfologi. 2025;35(1):29–39.
 53. Paval DR, Patton R, Mcdonald J, Skipworth RJE, Gallagher IJ, Laird BJ. A systematic review examining the relationship between cytokines and

cachexia in incurable cancer. Journal of cachexia, sarcopenia and muscle. 2022;44(October 2021):824–38.

54. Liu C, Zhang Q, Ruan G, Shen L, Xie H. Novel Diagnostic and Prognostic Tools for Lung Cancer Cachexia : Based on Nutritional and In fl ammatory Status. *Frontiers in oncology*. 2022;12(July):1–14.
55. Robinson TP, Counts B, Guttridge DC, Ostrowski MC, Zimmers TA, Koniaris LG. The impact of in fl ammation and acute phase activation in cancer cachexia. *Frontiers in immunology*. 2023 Oct 31;14:1207746.
56. Mounsey CA, Kanellakis NI, Freemantle N, Rahman NM. External validation of the LENT and PROMISE prognostic scores for malignant pleural effusion. *ERJ OPEN Res* [Internet]. 2025;11(June):2019–24. Available from: <http://dx.doi.org/10.1183/23120541.01019-2024>

